title: Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls.
abstract: Amyloid load in the brain using Pittsburgh compound B ((11)C-PIB) positron emission tomography (PET) and cerebral glucose metabolism using fluorodeoxyglucose ((18)F-FDG) PET were evaluated in patients with mild Alzheimer disease (AD, n = 18), mild cognitive impairment (MCI, n = 24), and controls (CTR, n = 18). ( 11)C-PIB binding potential (BP(ND)) was higher in prefrontal cortex, cingulate, parietal cortex, and precuneus in AD compared to CTR or MCI and in prefrontal cortex for MCI compared to CTR. For (18)F-FDG, regional cerebral metabolic rate for glucose (rCMRGlu) was decreased in precuneus and parietal cortex in AD compared to CTR and MCI, with no MCI-CTR differences. For the AD-CTR comparison, precuneus BP(ND) area under the receiver operating characteristic (ROC) curve (AUC) was 0.938 and parietal cortex rCMRGlu AUC was 0.915; for the combination, AUC was 0.989. ( 11)C-PIB PET BP(ND) clearly distinguished diagnostic groups and combined with (18)F-FDG PET rCMRGlu, this effect was stronger. These PET techniques provide complementary information in strongly distinguishing diagnostic groups in cross-sectional comparisons that need testing in longitudinal studies.
authors.affiliation: Division of Geriatric Psychiatry, Columbia University, New York, USA. dpd3@columbia.edu
authors.forename: D P
authors.initials: DP
authors.lastname: Devanand
authors.forename: Arthur
authors.initials: A
authors.lastname: Mikhno
authors.forename: Gregory H
authors.initials: GH
authors.lastname: Pelton
authors.forename: Katrina
authors.initials: K
authors.lastname: Cuasay
authors.forename: Gnanavalli
authors.initials: G
authors.lastname: Pradhaban
authors.forename: J S
authors.initials: JS
authors.lastname: Dileep Kumar
authors.forename: Neil
authors.initials: N
authors.lastname: Upton
authors.forename: Robert
authors.initials: R
authors.lastname: Lai
authors.forename: Roger N
authors.initials: RN
authors.lastname: Gunn
authors.forename: V
authors.initials: V
authors.lastname: Libri
authors.forename: Xinhua
authors.initials: X
authors.lastname: Liu
authors.forename: Ronald
authors.initials: R
authors.lastname: van Heertum
authors.forename: J John
authors.initials: JJ
authors.lastname: Mann
authors.forename: Ramin V
authors.initials: RV
authors.lastname: Parsey
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000000981:diagnostic imaging*; D000814:Aniline Compounds / Q000493:pharmacokinetics; D019540:Area Under Curve; D001921:Brain / Q000000981:diagnostic imaging*; D002531:Cerebellum / Q000000981:diagnostic imaging; D002851:Chromatography, High Pressure Liquid; D003072:Cognition Disorders / Q000000981:diagnostic imaging*; D003937:Diagnosis, Differential; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics; D006801:Humans; D007091:Image Processing, Computer-Assisted; D008279:Magnetic Resonance Imaging; D008297:Male; D008568:Memory / Q000502:physiology; D009483:Neuropsychological Tests; D049268:Positron-Emission Tomography; D012372:ROC Curve; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D013844:Thiazoles / Q000493:pharmacokinetics
chemical_list: C475519:2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole; D000814:Aniline Compounds; D019275:Radiopharmaceuticals; D013844:Thiazoles; D019788:Fluorodeoxyglucose F18